This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
LifeSci Capital Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
LifeSci Capital analyst Charles Zhu maintained a Hold rating on Repare Therapeutics yesterday. The company’s shares closed yesterday at $1.43.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Zhu is an analyst with an average return of -6.7% and a 41.23% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Merus, Kura Oncology, and Zymeworks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Repare Therapeutics.
RPTX market cap is currently $64.34M and has a P/E ratio of -0.52.
Read More on RPTX:
Disclaimer & DisclosureReport an Issue
- Closing Bell Movers: Victory Capital gains on S&P 400 inclusion
- Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib
- Repare Therapeutics Updates Severance Benefits for Executives
- Repare Therapeutics Holds Annual Shareholder Meeting
- Repare Therapeutics Strengthens Leadership with New Executive Appointment
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
